Koyfin Home > Directory > Health Care > Akebia Therapeutics > EBITDA Margin

Akebia Therapeutics EBITDA Margin Chart (AKBA)

Akebia Therapeutics annual/quarterly EBITDA Margin from 2016 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Akebia Therapeutics EBITDA Margin for the quarter ending June 06, 2020 was $-21m a -31.24% increase of 7m year over year
  • Akebia Therapeutics EBITDA Margin for the last 12 months ending June 06, 2020 was $-43m a -17.32% increase of 8m year over year
  • Akebia Therapeutics Annual EBITDA Margin for 2019 was $-51m a -40.19% increase of 20m from 2018
  • Akebia Therapeutics Annual EBITDA Margin for 2018 was $-71m a 41.04% decrease of -29m from 2017
  • Akebia Therapeutics Annual EBITDA Margin for 2017 was $-42m a -21,036.73% increase of 8,829m from 2016
Other Margins & Efficiency Metrics:
  • Akebia Therapeutics Return on Capital % for the quarter ending December 12, 2018 was -149.67 a 74.14% decrease of -110.96 year over year
  • Akebia Therapeutics Return on Equity % for the quarter ending December 12, 2018 was -247.98 a 76.13% decrease of -188.78 year over year
View Chart On Koyfin

Quarterly AKBA EBITDA Margin Data

06/2020$-21m
03/2020$-43m
12/2019$-94m
09/2019$-27m
06/2019$-29m
03/2019$-71m
12/2018$-101m
09/2018$-52m
06/2018$-73m
03/2018$-53m

Annual AKBA EBITDA Margin Data

2019$-51m
2018$-71m
2017$-42m
2016$-8,871m